What is the market's earnings forecast for Nu Skin Enterprises next quarter?

Did Nu Skin Enterprises beat or miss consensus estimates last quarter?

What were the key takeaways from Nu Skin Enterprises’s earnings call?

What is Nu Skin Enterprises's latest dividend and current dividend yield?

What factors drove the changes in Nu Skin Enterprises's revenue and profit?

What were the key takeaways from Nu Skin Enterprises's earnings call?

What does Nu Skin Enterprises do and what are its main business segments?

What guidance did Nu Skin Enterprises's management provide for the next earnings period?

- **Prysm iO Launch**: 100,000 devices targeted by end-2026, with subscription-based revenue to drive >6x customer lifetime value.
- **India Expansion**: Formal market opening in late 2026, focusing on digital-first infrastructure and localized products for middle class.
- **Financial Performance**: 2025 EPS up 51% to $1.27, with 2026 guidance of $0.80-$1.20 EPS, driven by operational efficiency and emerging markets.
- **Strategic Focus**: Transition year with 2026 growth return, prioritizing AI-powered wellness, India expansion, and cost optimization.

**【Management Opening Remarks】**
- B.G. Hunt highlighted the successful Mavely transaction, which strengthened the balance sheet and enabled strategic focus on intelligent wellness and emerging markets.
- CEO Ryan Napierski emphasized 2025 as a transformative year, with a 40% stock price increase and strategic priorities: Prysm iO launch, India market expansion, and operational efficiency improvements.

**【CEO Summary Section】**
- **Prysm iO Launch**: Targeting 100,000 device placements by end-2026, with subscription-based revenue potential. The platform leverages 400 million carotenoid data points to offer personalized wellness insights.
- **India Expansion**: Formal market opening anticipated in late 2026, with a localized product portfolio, digital-first infrastructure, and focus on emerging middle class.
- **Operational Transformation**: 2026 is a transition year with switching costs, but expected return to growth by year-end through cost optimization and channel alignment.

**【CFO Financial Commentary】**
- **2025 Performance**: Adjusted EPS of $1.27 (51% YoY growth), driven by 80bp gross margin expansion and $80.3 million in operating cash flow.
- **2026 Guidance**: Revenue $1.35B-$1.5B, EPS $0.80-$1.20, with tax rate at 35%. Key drivers: Prysm iO subscriptions, Latin America growth, and India market build-out.
- **Cost Management**: Selling expense ~40%, G&A aligned with revenue, and $142M remaining under share buyback program.

**【Q&A Highlights】**
- **Prysm iO Revenue Potential**: Device sales (~$30M for 100,000 units) and subscription monetization to be tracked post-Q3 2026 launch. Unit economics suggest 6x+ customer lifetime value.
- **India Risks & Opportunities**: Infrastructure challenges (manufacturing, logistics) but long-term potential as a $6.8T wellness market participant.
- **Portfolio Strengths**: Tru Face premium skincare line performing well in Latin America, with China and North America showing improvement.


Nu Skin Enterprises, Inc. (NUS) Q4 2025 Earnings Call Transcript

- **Revenue and Profitability**: Q3 2025 revenue of $364 million (within guidance), EPS of 34 cents (high end of range), with gross margin improving to 70.5%.
- **Growth Drivers**: Latin America up 53% YoY; Prism IO device to reach 10,000+ units in Q4 2025; India pre-market opening with digital-first model.
- **Strategic Focus**: Shifting North America to intelligent wellness; RISE segment (LifeDNA) outperformed; cautious 2025 guidance reflects Prism IO and India launch risks.

**【Management Opening Remarks】**
- B.G. Hunt provided an overview of the call, emphasizing forward-looking statements and non-GAAP financial measures. The company highlighted its Q3 2025 results and strategic priorities for growth.

**【CEO Summary Section】**
- **Q3 2025 Financial Highlights**: Revenue of $364 million (within guidance), EPS of 34 cents (high end of guidance). Gross margin improved to 70.5%, driven by core business optimization.
- **Strategic Growth Drivers**: 
  - **Latin America Growth**: 53% YoY growth, showcasing success in emerging markets.
  - **Prism IO Launch**: A portable intelligent wellness device with 10,000+ units expected in Q4 2025, targeting 300,000+ subscribed customers by 2026.
  - **India Expansion**: Pre-market opening in Q4 2025, focusing on a digital-first model with localized products (e.g., SeraNu skincare line).
- **Segment Performance**: RISE segment (LifeDNA) exceeded expectations, while North America faced macroeconomic challenges but showed sequential improvement.

**【CFO Financial Commentary】**
- **Gross Margin Expansion**: 70.5% (vs. 70.1% YoY), driven by product mix optimization and cost control.
- **Cost Efficiency**: Selling expenses decreased to 35.8% of revenue (from 39% YoY), with core business selling expense at 41.7%.
- **Liquidity and Capital Allocation**: $252 million in cash, $20 million debt reduction, and $152.4 million remaining under share repurchase authorization.
- **Guidance Update**: Full-year 2025 revenue guidance narrowed to $1.48–$1.51 billion, with EPS of $3.15–$3.25.

**【Q&A Highlights】**
- **India Strategy**: Pre-market opening with a focus on digital infrastructure and localized products, aiming to learn and adapt to regional market dynamics.
- **North America Restructuring**: Shift from beauty to intelligent wellness with Prism IO, leveraging salesforce engagement and subscription-based models.
- **Southeast Asia Growth**: Sequential improvement driven by Pacific markets (e.g., Australia, New Zealand) and strong TR90 body transformation product performance.


Nu Skin Enterprises, Inc. (NUS) Q3 2025 Earnings Call Transcript

- **Revenue and Profit Beats**: Q2 revenue $386M (high end of guidance), EPS $0.43 (vs. $0.20-$0.30), driven by cost efficiency.
- **Latin America Surge**: +100% YoY in revenue, customers, and leaders, fueled by simplified model and digital infrastructure.
- **Prysm iO Launch**: Palm-sized AI wellness device rolling out Q4 2025 to leaders, consumer launch H2 2026, with geographically customized LifePak products.
- **India Expansion**: Masstige brand for middle class, Q4 2025 premarket opening, formal launch mid-2026.
- **Margin Expansion**: Operating margin 8% (vs. 5.4% YoY), gross margin 77.5% in core business (up 140bps YoY).
- **Balance Sheet Strength**: Net cash positive ($264M cash), first time in 4 years, enabling strategic investments and shareholder returns.

**【Management Opening Remarks】**
- B.G. Hunt provided forward-looking statement and non-GAAP reconciliation disclaimers, setting the stage for the call's focus on Q2 performance and strategic updates.

**【CEO Summary Section】**
- **Q2 Performance Highlights**: Revenue of $386.1 million (high end of guidance), EPS of $0.43 (vs. $0.20-$0.30 guidance), driven by cost management and operational efficiency.
- **Segment Performance**: 
  - **Latin America**: +100% YoY in revenue, customers, and sales leaders, outperforming expectations.
  - **Japan**: Growth via subscription-based wellness business.
  - **South Korea/China**: Sequential improvement despite macro challenges.
  - **Rhyz Manufacturing**: +17% YoY growth, supporting rapid product launches (e.g., M-Smart in <2 months).
- **Strategic Priorities**:
  - **Prysm iO Launch**: Palm-sized AI wellness device measuring carotenoid levels, rolling out Q4 2025 to leaders, consumer launch H2 2026. Accompanied by geographically customized LifePak products (e.g., Vitamin E optimization).
  - **Developing Markets**: India strategy with masstige brand for middle class, Q4 2025 premarket opening, formal launch mid-2026.
  - **Project Accelerate**: Gross margin target of 78% for core business, operating margin of 8% in Q2 (vs. 5.4% YoY), cash to debt positive balance sheet.

**【CFO Financial Commentary】**
- **Q2 Financials**: 
  - Revenue: $386 million (neutral FX), EPS: $0.43 (vs. $0.21 YoY).
  - **Gross Margin**: 68.8% (vs. 70% YoY), core Nu Skin: 77.5% (up 140bps YoY).
  - **Selling Expense**: 33.2% of revenue (vs. 35.2% YoY), core Nu Skin: 40% (vs. 42.2% YoY).
  - **Operating Margin**: 8% (vs. 5.4% YoY), driven by cost reductions and shared services.
  - **Cash Flow**: $35.8 million from operations, net cash positive for first time in 4 years ($264M cash).
- **Guidance Update**: 
  - Q3: $360-390M revenue, $0.25-$0.35 EPS.
  - Full Year: $1.48-1.55B revenue, $3.05-3.25 EPS (adjusted: $1.15-1.35).

**【Q&A Key Highlights】**
- **Guidance Narrowing**: Latin America overperformance offset by North America, Korea/China uncertainty. India launch and Prysm iO could drive upper end of guidance.
- **Latin America Success**: Simplified model with 3 prongs: product portfolio (right price points), business model (retail profit + incentives), scalable digital infrastructure.
- **Cost Optimization**: 4Q of sequential gross margin improvement, inventory alignment with revenue, G&A efficiency via technology.
- **Capital Allocation**: Priority on Prysm iO, India, and R&D. Dividend continuation, share buyback ($157M remaining).

Nu Skin Enterprises, Inc. (NUS) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: $364.5M Q1 revenue, driven by 144% YoY Latin America surge.
- **Strategic Momentum**: Prysm iO device launch Q3/Q4 2025, India market entry Q4 2025.
- **Financial Health**: $204M cash, $239M debt (lowest in 10+ years), $0.23 EPS beat.
- **Operational Efficiency**: 3Qs of gross margin improvement, 76.7% core business margin.
- **Risk Mitigation**: Proactive supply chain strategies to navigate macro uncertainty.

**【CEO Key Highlights】**
- **Q1 Revenue**: $364.5M (high end of guidance), driven by 144% YoY growth in Latin America, offset by U.S./Canada macro pressures.
- **Strategic Priorities**: 
  1. Core Business Strengthening: $20B+ in sales compensation milestone; optimized sales plans in South Korea, Europe, & Latin America.
  2. Innovation Acceleration: Prysm iO launch Q3/Q4 2025, targeting 500K+ devices with 100M+ data points; India market entry Q4 2025 with localized products.
  3. Operational Efficiency: 3Qs of sequential gross margin improvement; 76.7% core business GM.

**【CFO Financial Breakdown】**
- **Income Statement**: 
  - GAAP EPS: $2.14 (includes $176M Mavely sale gain)
  - Adjusted EPS: $0.23 (vs. $0.09 prior year)
  - Gross Margin: 67.8% (67.8% core, 76.7% Rhyz)
  - Selling Expense: 32.5% (38.7% core, down 300bps YoY)
- **Balance Sheet**: 
  - Debt: $239M (lowest in 10+ years)
  - Cash: $204M
  - Share Repurchases: $5M (Q1); $157.4M remaining authorization
- **Q2 Outlook**: 
  - Revenue: $355-390M (2-3% FX headwind)
  - EPS: $0.20-0.30

**【Operational Updates】**
- **India Expansion**: Pre-launch Q4 2025, formal launch mid-2026 with locally-manufactured products & digital-first experience via Infosys partnership.
- **Prysm iO Rollout**: Limited quantities Q3/Q4 2025, global leader launches H1 2026, with LifePak product restages to align with geographic needs.
- **Supply Chain Resilience**: Diversified sourcing & inventory optimization to mitigate tariff risks; no near-term cost impact expected.

Nu Skin Enterprises (NUS)-8 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth & Strategic Wins**: Q4 revenue exceeded expectations, with Rhyz up 28% YoY and Mavely sale generating $250M (5x ROI). Prysm iO scanner set for 2025 launch.
- **Operational Excellence**: 7.7% operating margin (130bps YoY improvement), $70M free cash flow, and $110M debt reduction.
- **Market Focus**: Developing markets (Latin America, Southeast Asia) driving growth, offsetting China/South Korea challenges. Amazon strategy balances brand protection with e-commerce expansion.

**【CEO Summary Section】**
- **Q4 Revenue Performance**: Delivered $445.6 million, exceeding guidance with 28% YoY growth in Rhyz segment. Key drivers included the launch of ageLOC Tru Face peptide retinal complex and Mavely's $250 million sale, yielding a 5x return on investment.
- **Strategic Priorities for 2025**: 
  1. **Strengthen Core Nu Skin Business**: Refining product portfolio for developing markets (e.g., Latin America, Southeast Asia) and rolling out a social-first affiliate model.
  2. **Accelerate IO Innovation**: Launching Prysm iO, a non-invasive nutrient absorption scanner, in late 2025 with global rollout in 2026. IO platform now includes 25M connected treatments and 100M data points.
  3. **Operational Efficiency**: Targeting 50% portfolio optimization by end-2025, reducing debt by $110M in 2024, and improving free cash flow to $70M.
- **Market Challenges**: Persistent headwinds in China and South Korea, offset by growth in Latin America and Southeast Asia.

**【CFO Financial Commentary】**
- **Q4 Financial Highlights**: Adjusted EPS of $0.38 (vs. $0.37 prior year), 7.7% operating margin (up 130bps YoY). Gross margin 71.4%, with core Nu Skin at 76.6%.
- **Balance Sheet Strength**: Reduced debt by $110M in 2024, using Mavely proceeds to further deleverage. Free cash flow up $10M YoY to $70M. Dividends maintained at high industry yield.
- **2025 Outlook**: Revenue $1.48B-$1.62B (3% FX headwind), EPS $3.45-$3.85. Q1 revenue $345M-$365M, with EBITDA growth driven by cost restructuring.

**【Q&A Key Takeaways】**
- **China/South Korea Outlook**: Economic challenges expected to persist, with focus on pricing strategy and affiliate support.
- **Growth Markets**: Latin America, Southeast Asia, and Japan showing potential. Americas sequential growth driven by Rhyz and Tru Face launches.
- **Amazon Strategy**: Balancing brand integrity with accessibility, minimizing unauthorized reselling while leveraging Amazon's reach.

Actual											0.36	0.81	1.08	1.4	0.91	1.15	0.97	-0.18	0.76	0.67	-0.51	1.15	0.23	0.54	-0.74	0.37	0.09	0.21	0.17	0.38	0.23	0.43	0.34	0.29
Forecast											0.2484	0.6039	1.0007	1.1892	0.726	1.048	0.8575	0.9478	0.72	0.7857	0.37	0.4433	0.3	0.5333	0.6433	-0.025	0.0496	0.1672	0.1966	0.215	0.131	0.245	0.3	0.3
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+44.93%	+34.13%	+7.92%	+17.73%	+25.34%	+9.73%	+13.12%	-118.99%	+5.56%	-14.73%	-237.84%	+159.42%	-23.33%	+1.26%	-215.03%	+1580.00%	+81.45%	+25.60%	-13.53%	+76.74%	+75.57%	+75.51%	+13.33%	-3.33%

NUS

NUS fundamentals

NUS Q4 2025 Earnings

Earnings Call

You can ask Aime

NUS

NUS fundamentals

NUS Q4 2025 Earnings

Earnings Call

NUS Earnings Call Summary for Q4/20255:00 PM on Feb 12, 2026

NUS Earnings Call Summary for Q3/20255:00 PM on Nov 6, 2025

NUS Earnings Call Summary for Q2/20255:00 PM on Aug 7, 2025

NUS Earnings Call Summary for Q1/20255:00 PM on May 8, 2025

NUS Earnings Call Summary for Q4/20245:00 PM on Feb 13, 2025

You can ask Aime